Astec Lifesciences slumps after weak Q2 result

Astec Lifesciences lost 3.29% to Rs 548.70 at 13:36 IST on BSE after consolidated net profit dropped 40.27% to Rs 6.72 crore on 13.43% rise in total income to Rs 97.61 crore in Q2 September 2017 over Q2 September 2016.

The result was announced after market hours yesterday, 25 October 2017.

Meanwhile, the S&P BSE Sensex was up 19.45 points or 0.06% at 33,061.95. The S&P BSE Small-Cap index was up 126.84 points or 0.74% at 17,286.14.

On the BSE, 10,000 shares were traded on the counter so far as against the average daily volumes of 14,846 shares in the past one quarter. The stock had hit a high of Rs 559 and a low of Rs 535.55 so far during the day. The stock had hit a record high of Rs 694.80 on 20 December 2016 and a 52-week low of Rs 442 on 27 October 2016.

The stock had underperformed the market over the past one month till 25 October 2017, falling 5.37% compared with 4.57% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 3.59% as against Sensex's 2.04% rise. The scrip, however, outperformed the market in past one year, rising 22.91% as against Sensex's 18.70% rise.

The small-cap company has equity capital of Rs 19.52 crore. Face value per share is Rs 10.

Astec Lifesciences is a producer of agrochemicals and pharmaceutical intermediates.

Powered by Capital Market - Live News